Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze

Neuropharmacology

Volumn 36, Issue 8, 1997, Pages 1089-1097

  Cao, B J ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

1 PP; 5 HT(1A) receptors; Anxiety; Buspirone; Elevated plus maze; Mice; Proadifen

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; BUSPIRONE; DRUG METABOLITE; ENZYME INHIBITOR; PROADIFEN;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; ETHOLOGY; GROOMING; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BIOTRANSFORMATION; BUSPIRONE; DRUG ANTAGONISM; MALE; MAZE LEARNING; MICE; PROADIFEN; SEROTONIN AGONISTS;

EID: 0030806429     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00094-4     Document Type: Article

References (41)

1. Abe M., Tabata R., Saito K.-I., Matsuda T., Baba A. and Egawa M. (1996) Novel benzodioxan derivative, 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole Hc1 (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models. Journal of Pharmacology and Experimental Therapeutics 278: 898-905.
2. Amano M., Goto A., Sakai A., Achiha M., Hara N., Takahashi N., Hara C. and Ogawa N. (1993) Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats. Japanese Journal of Pharmacology 61: 311-317.
3. Cao B.-J. and Rodgers R. J. (1996) Different behavioural profiles of R(+)- and S(-)-enantiomers of 8-hydroxy-2-(din-propylamino)tetralin (8-OH-DPAT) in the marine elevated plus-maze. Behavioural Pharmacology 7: 810-819.
4. 1A receptor antagonist, has anxiolytic-like profile in the murine elevated plus-maze. Psychopharmacology 129: 365-371.
5. 1A. Pharmacology, Biochemistry and Behaviour. In press.
6. 1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN 190. Pharmacology, Biochemistry and Behaviour. In press.
7. Cervo L., Grignaschi G. and Samanin R. 1997c Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite. Life Sciences 43: 2095-2102.
8. Cole J. C. and Rodgers R. J. (1994) Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 114: 288-296.
9. 2-adrenoceptor mediation. Psychopharmacology 118: 425-436.
10. Cutler N. R., Sramek J. J. and Kurtz N. M. (1996) Anxiolytic compounds. Perspectives in drug development. Wiley, Chichester.
11. Cullen W. K. and Rowan M. J. (1994) Gepirone and 1-(2-pyrimidinyl)-piperazine-induced reduction of aversively evoked ultrasonic vocalisation in the rat. Pharmacology, Biochemistry and Behaviour 48: 301-306.
12. De Vry J., Benz U., Schreiber R. and Traber J. (1993) Shocked-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. European Journal of Pharmacology 249: 331-339.
13. 1A receptor agonists in the mouse. British Journal of Pharmacology 109: 1046-1052.
14. Gammans R. E., Mayol R. E. and Eison M. S. (1983) Concentration of buspirone and 1-(2-pyrimidinyl)-piperazine, a metabolite, in rat brain. Federation Proceedings 42: 377.
15. Griebel G. (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacological Therapy 65: 319-395.
16. 2-adrenoceptors in the rat brain. European Journal of Pharmacology 180: 183-186.
17. 2-Adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. European Journal of Pharmacology 155: 129-137.
18. Handley S. L., McBlane J. W., Critchley M. A. E. and Njung'e K. (1993) Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behavioral Brain Research 58: 203-210.
19. Handley S. L. and Mithani S. (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedeberg's Archives of Pharmacology 327: 1-5.
20. 1A receptors. Journal of Psychiatry and Neuroscience 21: 101-108.
21. Hogg S. (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology, Biochemistry and Behaviour 54: 21-30.
22. Holmberg G. and Gershon S. (1961) Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia 2: 93-106.
23. 1A receptors. Journal of Pharmacology and Experimental Therapeutics 264: 863-872.
24. 1A receptors. European Journal of Pharmacology 294: 617-624.
25. 1A agonists in the learned helplessness paradigm in rats. Psychopharmacology 104: 275-278.
26. Matsuda T., Yoshikawa T., Suzuki M., Anaso S., Somboonthum P., Takuma K., Nakano Y., Morita T., Nakasu Y., Kim H. S., Egawa M., Tobe A. and Baba A. (1995) Novel benzodioxan derivative, 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole Hcl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin 1A receptors. Japanese Journal of Pharmacology 69: 357-366.
27. Mennini T., Caccia S. and Garattini S. (1987) Mechanism of action of anxiolytic drugs. Progress in Drug Research 31: 315-347.
28. Miller L. G., Thompson M. L., Byrnes J. J., Greenblatt D. J. and Shemer A. (1992) Kinetic, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2 pyrimidinyl-piperazine. Journal of Clinical Psychopharmacology 12: 341-345.
29. Mongeau R., Blier P. and Montigny C. de (1993) In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of α2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology 347: 266-272.
30. Moser P. C. (1989) An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology 99: 48-53.
31. Nocon H., Daniel W., Danek L. and Melzacka M. (1990) Cerebral pharcokinetics of ipsapirone in rats after different routes of administration. Journal of Pharmacy and Pharmacology 42: 642-645.
32. Przegalinski E., Tatarczynska E. and Chojnacka-Wojcik E. (1990) Antidepressant-like activity of ipsapirone, buspirone and gepirone in the forced swimming test in rats pretreated with proadifen. European Journal of Pharmacology 183: 1906.
33. 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. British Journal of Pharmacology 116: 2081-2089.
34. Rodgers R. J. and Cole J. C. (1994a) The elevated plus-maze: pharmacology, methodology and ethology. In Ethology and psychopharmacology (Cooper S. J. and Hendrie C. A., Eds), pp. 9-44. J. Wiley and Sons, Chichester.
35. 1A receptor antagonist, in the murine elevated plus-maze test. European Journal of Pharmacology 261: 321-325.
36. Rodgers R. J. and Johnson N. J. T. (1995) Factor analysis of spatiotemporal and ethological measures in the elevated plus-maze test of anxiety. Pharmacology, Biochemistry and Behaviour 52: 297-303.
37. Sanger D. J. and Schoemaker H. (1992) Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5-HT1A receptors. Psychopharmacology 108: 85-92.
38. 1A receptor agonist. Fundamental Clinical Pharmacology 7: 413-427.
39. Söderpalm B., Hjorth S. and Engel J. A. (1989) Effects of 5-HT2 receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacology, Biochemistry and Behaviour 98: 898-907.
40. Tollefson G. D., Lancaster S. P. and Montague-Clouse J. (1991) The association of buspirone and its metabolite 1-pyrimidinyl piperazine in the remission of comorbid anxiety with depressive symptoms. Psychopharmacology Bulletin 27: 163-170.
41. Wright I. K., Upton N. and Marsden C. A. (1992) Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology 109: 338-346.